TG2 promotes amyloid beta aggregates: Impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer's disease.

[1]  Yuan Zhang,et al.  Bromo-protopine, a novel protopine derivative, alleviates tau pathology by activating chaperone-mediated autophagy for Alzheimer’s disease therapy , 2022, Frontiers in Molecular Biosciences.

[2]  A. Bera,et al.  Reduction of kinesin I heavy chain decreases tau hyperphosphorylation, aggregation, and memory impairment in Alzheimer’s disease and tauopathy models , 2022, Frontiers in Molecular Biosciences.

[3]  K. Cheung,et al.  Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer’s Disease , 2022, International journal of molecular sciences.

[4]  Simiao Chen,et al.  Role of Calcium Homeostasis in Alzheimer’s Disease , 2022, Neuropsychiatric disease and treatment.

[5]  A. Smit,et al.  Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice , 2022, Neuropathology and applied neurobiology.

[6]  B. Drukarch,et al.  The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer’s Disease , 2022, Cells.

[7]  J. Fuentealba,et al.  Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure , 2021, Neural regeneration research.

[8]  M. Germain,et al.  Mitochondria Endoplasmic Reticulum Contact Sites (MERCs): Proximity Ligation Assay as a Tool to Study Organelle Interaction , 2021, Frontiers in Cell and Developmental Biology.

[9]  Lehui Xiao,et al.  Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of Aβ Fibrillation. , 2021, Nano letters.

[10]  C. Rivas,et al.  PrPC as a Transducer of Physiological and Pathological Signals , 2021, Frontiers in Molecular Neuroscience.

[11]  Hai-bin Luo,et al.  Curved carbon photo-oxygenation catalysts for the suppression and nanoscopic imaging of β-amyloid peptides fibrillation , 2021, Nano Research.

[12]  J. Fuentealba,et al.  Increased P2×2 receptors induced by amyloid-β peptide participates in the neurotoxicity in alzheimer's disease. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Nittaya Boonmuen,et al.  A Novel Methodology Using Dexamethasone to Induce Neuronal Differentiation in the CNS-Derived Catecholaminergic CAD Cells , 2021, Cellular and Molecular Neurobiology.

[14]  Nan Wang,et al.  The MAMs Structure and Its Role in Cell Death , 2021, Cells.

[15]  T. Calì,et al.  Mitochondria Associated Membranes (MAMs): Architecture and physiopathological role. , 2021, Cell calcium.

[16]  Garam Lee,et al.  Alzheimer's disease drug development pipeline: 2021 , 2021, Alzheimer's & dementia.

[17]  Haiqiang Jin,et al.  Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer’s disease , 2021, Clinical science.

[18]  Lin Wei,et al.  Length-Dependent Distinct Cytotoxic Effect of Amyloid Fibrils beyond Optical Diffraction Limit Revealed by Nanoscopic Imaging. , 2020, ACS nano.

[19]  F. Checler,et al.  Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimer’s Disease , 2020, International journal of molecular sciences.

[20]  Hai-bin Luo,et al.  Deep Red Blinking Fluorophore for Nanoscopic Imaging and Inhibition of β-Amyloid Peptide Fibrillation. , 2020, ACS nano.

[21]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[22]  J. Im,et al.  Transglutaminase 2 Depletion Attenuates α-Synuclein Mediated Toxicity in Mice , 2020, Neuroscience.

[23]  J. Fuentealba,et al.  Changes in PGC‐1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model , 2020, Frontiers in Pharmacology.

[24]  M. Hallbeck,et al.  Oligomeric amyloid-β induces early and widespread changes to the proteome in human iPSC-derived neurons , 2020, Scientific Reports.

[25]  V. Zachariou,et al.  Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research , 2019, Biomedicines.

[26]  D. Praticò,et al.  Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer’s disease , 2019, Nature Communications.

[27]  W. Mobley,et al.  Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses , 2019, Front. Neurosci..

[28]  C. Villalobos,et al.  Amyloid β Oligomers Increase ER-Mitochondria Ca2+ Cross Talk in Young Hippocampal Neurons and Exacerbate Aging-Induced Intracellular Ca2+ Remodeling , 2019, Front. Cell. Neurosci..

[29]  P. Pinton,et al.  Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. , 2018, Cell reports.

[30]  K. Chung,et al.  New insight into transglutaminase 2 and link to neurodegenerative diseases , 2018, BMB reports.

[31]  M. Andjelkovic,et al.  A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[32]  Karsten Melcher,et al.  Amyloid beta: structure, biology and structure-based therapeutic development , 2017, Acta Pharmacologica Sinica.

[33]  A. Makarov,et al.  Amyloid β Modification: A Key to the Sporadic Alzheimer's Disease? , 2017, Front. Genet..

[34]  A. Buisson,et al.  The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation , 2017, Science Signaling.

[35]  Dima Kozakov,et al.  The ClusPro web server for protein–protein docking , 2017, Nature Protocols.

[36]  L. Mucke,et al.  The integration site of the APP transgene in the J20 mouse model of Alzheimer's disease. , 2017, Wellcome open research.

[37]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[38]  A. Smit,et al.  Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer’s disease mouse models , 2016, Scientific Reports.

[39]  P. Coussons,et al.  Biological Functionalities of Transglutaminase 2 and the Possibility of Its Compensation by Other Members of the Transglutaminase Family , 2014, TheScientificWorldJournal.

[40]  E. Schon,et al.  Upregulated function of mitochondria-associated ER membranes in Alzheimer disease , 2012, The EMBO journal.

[41]  W. Kim,et al.  Cognitive phenotyping of amyloid precursor protein transgenic J20 mice , 2012, Behavioural Brain Research.

[42]  J. Fuentealba,et al.  Synaptic silencing and plasma membrane dyshomeostasis induced by amyloid-β peptide are prevented by Aristotelia chilensis enriched extract. , 2012, Journal of Alzheimer's disease : JAD.

[43]  M. Piacentini,et al.  TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy , 2012, Amino Acids.

[44]  Karin D. Quiñones,et al.  Synaptic failure and adenosine triphosphate imbalance induced by amyloid‐β aggregates are prevented by blueberry‐enriched polyphenols extract , 2011, Journal of neuroscience research.

[45]  M. Piacentini,et al.  Type 2 transglutaminase in Huntington’s disease: a double‐edged sword with clinical potential , 2010, Journal of internal medicine.

[46]  N. Ferguson,et al.  Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.

[47]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[48]  K. Hitomi,et al.  A specific colorimetric assay for measuring transglutaminase 1 and factor XIII activities. , 2009, Analytical biochemistry.

[49]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[50]  Shaomin Li,et al.  Transglutaminase Induces Protofibril-like Amyloid β-Protein Assemblies That Are Protease-resistant and Inhibit Long-term Potentiation* , 2008, Journal of Biological Chemistry.

[51]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[52]  J. Troncoso,et al.  Transglutaminase‐Induced Cross‐Linking of Tau Proteins in Progressive Supranuclear Palsy , 2000, Journal of neuropathology and experimental neurology.

[53]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .